NASDAQ:REGNRegeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REGN stock has increased by 28.9% and is now trading at $598.86.
View which stocks have been most impacted by COVID-19.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) posted its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $1.57. The biopharmaceutical company earned $1.95 billion during the quarter, compared to analysts' expectations of $1.74 billion. Regeneron Pharmaceuticals had a return on equity of 26.71% and a net margin of 37.30%. Regeneron Pharmaceuticals's revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the business earned $6.02 EPS.
View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals declared that its Board of Directors has authorized a stock buyback plan on Tuesday, November 5th 2019, which permits the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 2.9% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's management believes its stock is undervalued.

27 Wall Street analysts have issued twelve-month price objectives for Regeneron Pharmaceuticals' shares. Their forecasts range from $325.00 to $800.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $592.78 in the next twelve months. This suggests that the stock has a possible downside of 1.0%.
View analysts' price targets for Regeneron Pharmaceuticals.

News stories about REGN stock have trended very negative on Wednesday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a coverage optimism score of -3.9 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a decrease in short interest during the month of July. As of July 31st, there was short interest totaling 1,990,000 shares, a decrease of 6.1% from the July 15th total of 2,120,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.9% of the shares of the stock are sold short.
View Regeneron Pharmaceuticals' Short Interest.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Johnson & Johnson (JNJ), Micron Technology (MU), Walt Disney (DIS), Visa (V) and salesforce.com (CRM).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.76%), Bank of New York Mellon Corp (0.70%), Sumitomo Mitsui Trust Holdings Inc. (0.44%), Swiss National Bank (0.44%), First Trust Advisors LP (0.33%) and LSV Asset Management (0.29%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., LSV Asset Management, Toronto Dominion Bank, Bank of Nova Scotia, NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., Cannell Peter B & Co. Inc., and AJO LP. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, and Sanofi.
View insider buying and selling activity for Regeneron Pharmaceuticals.

REGN stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Swiss National Bank, Bank of New York Mellon Corp, Robeco Institutional Asset Management B.V., First Trust Advisors LP, Sumitomo Mitsui Trust Holdings Inc., Mn Services Vermogensbeheer B.V., and State of Wisconsin Investment Board.
View insider buying and selling activity for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $598.86.

Regeneron Pharmaceuticals has a market capitalization of $65.89 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]